HIMS trades 13.3% below Wall Street's consensus target of $32.17.
Last 12 months price action with 12-month analyst target path
The base valuation assumes HIMS achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 20 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Hims & Hers Health, Inc. (HIMS) has a Wall Street consensus price target of $32.17, based on estimates from 20 covering analysts. With the stock currently trading at $28.39, this represents a potential upside of +13.3%. The company has a market capitalization of $6.33B.
Analyst price targets range from a low of $24.50 to a high of $42.00, representing a 54% spread in expectations. The median target of $32.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 7 analysts rating the stock as a Buy or Strong Buy,13 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, HIMS trades at a trailing P/E of 55.7x. Analysts expect EPS to grow +3.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $6.33, with bear and bull scenarios of $3.99 and $8.33 respectively. Model confidence stands at 59/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 TDOCTeladoc Health, Inc. | $1.1B | $6.13 | $8.83 | +44.0% | Hold | — | 42 |
 DOCSDoximity, Inc. | $5.0B | $26.57 | $27.36 | +3.0% | Hold | 19.7x | 24 |
 OPRXOptimizeRx Corp. | $143M | $7.60 | $10.25 | +34.9% | Buy | 8.3x | 15 |
 WELLWelltower Inc. | $165.7B | $229.94 | $258.38 | +12.4% | Buy | 81.0x | 35 |
 NVONovo Nordisk A/S | $169.5B | $38.17 | $44.67 | +17.0% | Buy | 1.7x | 39 |
 LLYEli Lilly and Company | $1.1T | $1152.70 | $1343.07 | +16.5% | Buy | 31.7x | 45 |
 AMWLAmerican Well Corporation | $225M | $13.21 | $13.00 | -1.6% | Hold | — | 15 |
 TALKTalkspace, Inc. | $879M | $5.25 | $4.38 | -16.6% | Hold | 40.6x | 10 |
 GDRXGoodRx Holdings, Inc. | $1.2B | $3.32 | $4.19 | +26.2% | Hold | 10.9x | 24 |
 HCATHealth Catalyst, Inc. | $127M | $1.72 | $1.77 | +2.9% | Buy | — | 22 |
Quick answers to the most common questions about buying HIMS stock.
Hims & Hers Health, Inc. (HIMS) has a consensus 12-month price target of $32.17, implying 13.3% upside from $28.39. The 20 analysts covering HIMS see moderate appreciation potential.
HIMS has a consensus rating of "Hold" based on 20 Wall Street analysts. The rating breakdown is mixed, with 13 Hold ratings making up the largest segment. The consensus 12-month price target of $32.17 implies 13.3% upside from current levels.
HIMS's current price is $28.39 with a consensus target of $32.17 (13.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $42 for HIMS, while the most conservative target is $24.5. The consensus of $32.17 represents the median expectation. Our quantitative valuation model projects a bull case target of $8 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
HIMS is well covered by analysts, with 20 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 13 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month HIMS stock forecast based on 20 Wall Street analysts shows a consensus price target of $32.17, with estimates ranging from $24.5 (bear case) to $42 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $6, with bear/bull scenarios of $4/$8.
Our quantitative valuation model calculates HIMS's fair value at $6 (base case), with a bear case of $4 and bull case of $8. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 59/100.
Wall Street analysts are optimistic on HIMS, with a "Hold" consensus rating and $32.17 price target (13.3% upside). 7 of 20 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
HIMS analyst price targets range from $24.5 to $42, a 54% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $32.17 consensus represents the middle ground. Our model's $4-$8 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.